Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
Loading
Price to Sales: Discounted ValuationCompressed
Percentile Rank29
3Y CAGR-20.5%
5Y CAGR-14.3%
Year-over-Year Change
Price-to-sales ratio
3Y CAGR
-20.5%/yr
vs -27.0%/yr prior
5Y CAGR
-14.3%/yr
Recent deceleration
Acceleration
+6.5pp
Accelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
2 yr
Consecutive growthCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 14.03 | +5.0% |
| 2024 | 13.36 | +2.2% |
| 2023 | 13.08 | -53.1% |
| 2022 | 27.88 | +17.2% |
| 2021 | 23.79 | -21.5% |
| 2020 | 30.32 | -47.0% |
| 2019 | 57.26 | -41.5% |
| 2018 | 97.91 | -23.5% |
| 2017 | 127.96 | +88.3% |
| 2016 | 67.96 | - |